undamentalytics Newsletter
Sign in

Pyxis Oncology, Inc. (PYXS) stock

Add to watchlist

Add holding +

NASDAQ: PYXS Nasdaq Biotechnology

Pyxis Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Pyxis Oncology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling1 purchase and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds31 adding, 34 cuttingOf 20 active managers that changed their stake, 8 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 14% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -554.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -358.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 80.2% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 3.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 126% and a beta of 1.4 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2025 Q4

Filed March 23, 2026
Earnings per share
-$0.40 against an average estimate of -$0.35: missed by 14.3%
Revenue
$11m
Share reaction
-5.3% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 2, 2026; average EPS estimate -$0.28

Pyxis Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.6%
  • 1 week0.0%
  • 1 month-21.0%
  • This year+47.0%
  • 1 year-52.5%
  • 5 years-87.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-1.40

Growth

Share count change
+3.3%

Cash

Free cash flow (TTM)
-$67.9M

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Leadership
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Pyxis Oncology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025
Share price$1.56$1.15
Market value$91m$71m
+ Net debt (− = net cash)−$19m−$15m
Enterprise value$72m$56m
Multiples
Price / sales 5.6x5.2x
Price / earnings ——
Price / free cash flow ——
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.21 +5% $19440 −100%
Next −$1.11 +9% $3m +14189%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.9% on 90 days ago. In the last 30 days, 1 analyst raised Pyxis Oncology, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Pyxis Oncology, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.22 Current fiscal year, 60 days ago: −$1.22 Current fiscal year, 30 days ago: −$1.22 Current fiscal year, 7 days ago: −$1.22 Current fiscal year, Now: −$1.21 −$1.21 Next fiscal year, 90 days ago: −$1.21 Next fiscal year, 60 days ago: −$1.20 Next fiscal year, 30 days ago: −$1.13 Next fiscal year, 7 days ago: −$1.13 Next fiscal year, Now: −$1.11 −$1.11

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.22−$1.21
60 days ago −$1.22−$1.20
30 days ago −$1.22−$1.13
7 days ago −$1.22−$1.13
Now −$1.21−$1.11

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.35 −$0.40 −14.3%
Mar 2026 −$0.35 −$0.37 −4.7%
Dec 2025 −$0.34 −$0.29 +14.4%
Sept 2025 −$0.34 −$0.35 −3.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Oct 2026
Buy889%
Hold111%
Sell00%

Monthly trend

  1. Oct 2026819
  2. Sep 202618110
  3. Aug 202618110
  4. Jul 20261719

Counts of recommendations published by analysts covering Pyxis Oncology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.2%
of tradable shares
Days to cover
3.56
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
55%
of shares
Held by insiders
10.1%
of shares
Employees
56
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
PYXS−88%+34%−13%−26%+47%
Industry peers (median)−56%−18%−29%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
PYXS17%50%33%67%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
PYXS−90%−77%−77%−80%−57%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 8, 2021: 94% from November 4, 2021 to April 8, 2025. Getting back needed a 1455% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.06 – $5.34
From 52-week high
−68.4%
vs 50-day average
−35.7%
vs 200-day average
−21.7%
Volatility (1 year)
126%
Beta vs S&P 500
1.35

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±9.7%
After a week
4 up, 8 down
typical move ±14.0%
After a month
7 up, 5 down
typical move ±27.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −5.3% +0.5% −1.9% +7.9%
May 14, 2026 −13.0% −0.4% −26.0% −33.6%
March 23, 2026 −7.5% +0.7% −13.6% +27.9%
November 3, 2025 +9.6% −1.0% +34.0% +29.2%
August 14, 2025 +15.0% −0.2% +23.4% +77.6%
May 15, 2025 +13.1% +1.1% +12.1% +13.1%
March 18, 2025 −7.8% 0.0% −0.9% −19.5%
November 12, 2024 −9.7% −0.3% −12.2% −67.9%
August 14, 2024 −1.2% +2.0% +4.6% +8.9%
May 14, 2024 −1.9% +1.7% −6.8% −7.9%
March 21, 2024 −26.5% +0.1% −21.5% −16.6%
November 7, 2023 −6.3% +0.4% −10.9% +19.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2024 Dec 2024 2025 Dec 2025
Income
Revenue 16 14
Gross profit 16 11
EBITDA −86 −80
Operating income −89 −84
Net income −77 −80
Diluted EPS −$1.32 −$1.28
Growth (year on year)
Revenue — −14.2%
Margins
Gross margin 97.1% 82.8%
EBITDA margin −535.6% −576.6%
Operating margin −554.1% −609.2%
Net margin −478.9% −574.5%
Free-cash-flow margin −358.7% −458.3%
Cash flow
Cash from operations −58 −64
Capital spending 0 0
Free cash flow −58 −64
Stock-based pay 13 12
Free cash flow after stock pay −71 −75
Balance sheet
Cash 19 15
Total debt 0 0
Net debt (negative = net cash) −19 −15
Diluted shares 58m 62m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $55m
Short-term assets $37mLonger-term assets $18m
What it owes, and who funded it · $55m
Short-term liabilities $27mLonger-term liabilities $16mShareholders' equity $11m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $27m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $16m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Pyxis Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+3.3%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PYXS KROS PRQR CTMX CELU ALEC Median
Revenue, last 12 months $16m $15m $18m $18m $19m $14m $55m
Revenue growth, last 12 months — −93.6% −12.1% −87.0% −58.1% −82.9% 12.6%
Revenue growth, 3-year average — — — −38.7% 7.2% −48.6% 13.7%
Revenue growth, latest quarter — −100.0% — −92.4% −5.3% −57.8% 10.2%
Gross margin 97.1% — — — 19.2% — 82.9%
Operating margin −554.1% −682.3% −273.1% −476.2% −264.3% −912.4% −191.1%
Operating margin, 3-year average — <−999% — −146.9% −204.2% −472.3% −363.5%
Net margin −478.9% −559.2% −265.2% −435.2% −245.7% −850.1% −172.8%
Cash from operations / revenue −357.2% −322.7% −331.9% −450.3% −47.8% <−999% −168.8%
Free-cash-flow margin −358.7% −326.1% −338.3% −450.7% −80.1% <−999% −168.1%
Free-cash-flow margin, 3-year average — <−999% — −192.6% −50.3% −600.8% −310.0%
Stock pay / revenue 80.2% 153.8% 25.2% 55.4% 66.5% 120.9% 20.7%
Change in share count 3.3% −31.6% 22.4% 88.7% 24.7% 9.7% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Sale of Royalty Rights $11M 79.7% ▲ 38.0%
Milestone Revenue $2.8M 20.3% —
Royalty $0 0.0% ▼ 100.0%

From Pyxis Oncology, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$101M
Institutions reporting
76
Shares held vs prior quarter
▲ 24.8%
Positions opened / closed
9 / 10

Top buyers and sellers, Q2 2026: 31 institutions bought and 34 sold ; the biggest buyer was Gordonmd Global Investments LP (+5.9M shares) and the biggest seller 683 Capital Management, LLC (−437K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gordonmd Global Investments LP $30.2M 10.0M 29.8% ▲ 143.2%
Pfizer Inc $19.5M 7.0M 19.3% 0.0%
Laurion Capital Management LP $14.8M 4.9M 14.6% ▼ 1.9%
Vanguard Capital Management LLC $6.2M 2.1M 6.2% ▲ 2.1%
Atle Fund Management AB $2.9M 966K 2.9% —
Blackrock, Inc. $2.6M 868K 2.6% ▲ 10.0%
Palo Alto Investors LP $2.6M 864K 2.6% ▼ 14.5%
Marshall Wace, LLP $2.5M 831K 2.5% ▲ 134.3%
Renaissance Technologies LLC $2.3M 772K 2.3% ▼ 13.1%
Geode Capital Management, LLC $1.8M 592K 1.8% ▼ 1.0%
Woodline Partners LP $1.6M 524K 1.6% New
683 Capital Management, LLC $1.4M 459K 1.4% ▼ 48.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pyxis Oncology, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 1 trade by 1 insider, last 12 months Insider sales History → $107,100 1 trade by 1 insider · 100% under pre-set plans
Net ▼ $107,100 net selling
Insider Date Trade Shares Price Value
Gordonmd Global Investments Lp 10% owner October 1, 2026 Buy 5,517,000 — $0
Dupont Jakob Director June 30, 2026 Sell pre-set plan 35,000 $3.06 $107,100

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 23, 2026
  • November 3, 2025
  • August 14, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Pyxis Oncology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Pyxis Oncology, Inc. in brief

What does Pyxis Oncology, Inc. do?
Pyxis Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Pyxis Oncology, Inc.'s stock ticker?
Pyxis Oncology, Inc. trades under the ticker PYXS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Pyxis Oncology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gordonmd Global Investments LP, Pfizer Inc and Laurion Capital Management LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Pyxis Oncology, Inc.'s market cap?
On December 31, 2025, Pyxis Oncology, Inc.'s market capitalisation was about $71.5M and net debt of -$15.4M. Market figures come from third-party market data and may be delayed.
Who are Pyxis Oncology, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Pyxis Oncology, Inc. are Keros Therapeutics, Inc., Proqr Therapeutics N.V., Cytomx Therapeutics, Inc., Celularity Inc and Alector, Inc. The side-by-side comparison below sets their revenue, margins and growth against Pyxis Oncology, Inc.'s.
Are insiders buying or selling Pyxis Oncology, Inc. stock?
Over the last 12 months, Pyxis Oncology, Inc.'s directors and officers reported 1 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.